Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltartoxatug vs human tetanus immunoglobulin for post-traumatic tetanus passive immunization
ChiCTR2600120402Phase 4Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of siltartoxatug in open wound and Physical trauma (2 arms), sponsored by Army Medical Center of PLA. Primary endpoint: Incidence of any adverse events (AEs) within 7 days after administration. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
siltartoxatug
03
Conditions
open woundPhysical trauma
Beyond the preview
Go deeper on ChiCTR2600120402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120402.